News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Conference News AHA 2025 CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia Todd Neale November 08, 2025
News Conference News ESC 2025 ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients Michael O'Riordan September 10, 2025
News Conference News EAS 2025 Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM Yael L. Maxwell May 08, 2025
News Conference News AHA 2024 ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS Michael O'Riordan November 21, 2024
News Conference News AHA 2024 Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III Caitlin E. Cox November 21, 2024
News Conference News ESC 2024 Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events Michael O'Riordan September 01, 2024
News Conference News ESC 2024 Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events Caitlin E. Cox August 31, 2024
News Conference News ACC 2024 BE ACTIVE: Gaming for Points and Money Can Boost Step Counts L.A. McKeown April 11, 2024
News Conference News ACC 2024 Need a Statin for Primary Prevention? There’s an App for That Michael O'Riordan April 10, 2024
News Conference News ACC 2024 Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL Yael L. Maxwell April 09, 2024
News Conference News AHA 2023 Automatic Scripts, Pharmacist Phone Calls Boost Statin Prescribing Shelley Wood November 14, 2023
News Conference News AHA 2023 Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study Michael O'Riordan November 13, 2023
News Conference News AHA 2023 New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference? Shelley Wood November 13, 2023
News Conference News EACTS 2023 SWEDEHEART Hints at Mortality Benefit With Statins After SAVR Michael O'Riordan October 05, 2023
News Conference News ESC 2023 ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran Michael O'Riordan September 01, 2023
News Conference News EAS 2023 With New LDL Goalposts in FH, Combo Therapy Must Start Early Michael O'Riordan May 29, 2023
News Conference News EAS 2023 Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH Michael O'Riordan May 24, 2023
News Conference News EAS 2023 High LDL, Poor Treatment, Early Death: HoFH Registry Paints Grim Picture Michael O'Riordan May 23, 2023
News Conference News ACC 2023 Diabetic Patients in Middle East, Africa Overburdened by ASCVD Michael O'Riordan March 14, 2023